#227 Baffled by NAFLD?

Jul 27, 2020, 07:00 AM

Swim through the sea of acronyms as Dr Scott Matherly (@liverprof) helps us become a little less baffled by the thought of NAFLD. We discuss the initial diagnosis of fatty liver disease, indications for additional evaluation with imaging and/or biopsy, and potential treatment options. With a quarter of the world affected, it’s crucial to understand the various forms of disease and how to counsel patients about this all-too-common condition!

Show Notes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME!


Credits

  • Written and Produced by: Elena Gibson MD
  • Infographic and Cover Art: Elena Gibson MD
  • Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP
  • Editor: Emi Okamoto MD (written materials); Clair Morgan of nodderly.com
  • Guest: Scott Matherly MD

Sponsor: Pediatrics On Call


Sponsor:  VCU Health Continuing Education to offer continuing education credits for physicians and other healthcare professionals. Check out curbsiders.vcuhealth.org and create your FREE account!


Time Stamps

  • 00:00 Intro
  • 03:15 Guest one-liner; Picks of the Week*
:
  • 08:15 Sponsor
  • 08:50 Case from Kashlak part 1; What is hepatic steatosis?
  • 11:43 NAFLD acronyms and definitions
  • 18:20 Alcohol and Fatty Liver
  • 23:15 Initial Evaluation of NAFLD
  • 35:12 Dr Matherly’s piel to patients with fatty
  • 41:11 NASH/Fibrosis Risk Assessment
  • 48:54 Outcomes in NASH with Fibrosis
  • 51:20 Statins are safe in liver disease
  • 56:15 Treatment Options (surgery, Vitamin E, Pioglitazone, SLGT2 inhibitors and GLP1 agonists; Coffee?!)
  • 71:42 Take home points and Outro